Search

Your search keyword '"Oki, Yasuhiro"' showing total 1,058 results
Start Over Author "Oki, Yasuhiro"
1,058 results on '"Oki, Yasuhiro"'

1. Cohomological properties of multinorm-one tori

Author

Liang, Pei-Xin, Oki, Yasuhiro, and Yu, Chia-Fu

Subjects
Mathematics - Number Theory
Abstract

In this paper we investigate the Tate--Shafarevich group Sha^1(k, T) of a multinorm-one torus $T$ over a global field $k$. We establish a few functorial maps among cohomology groups and explore their relations. Using these properties and relations we obtain a few basic structural results for Sha^1(k, T) and extend a few results of Bayer-Fluckiger--Lee--Parimala [Adv. in Math., 2019] to some more general multinorm-one tori. We also give a uniform proof of a result of Demarche--Wei for a criterion of the vanishing of Sha^1(k, T), and of the main result of Pollio [Pure App. Math. Q., 2014] for the case where the \'etale $k$-algebra in question is a product of two abelian extensions. Moreover, we improve the explicit description of Sha^1(k, T) in Lee [J. Pure Appl. Alg., 2022] by removing an intersection condition., Comment: 26 pages, comments welcome

Published
2023

2. The Hasse norm principle for some non-Galois extensions of square-free degree

Author

Oki, Yasuhiro

Subjects
Mathematics - Number Theory
Abstract

In this paper, we study the Hasse norm principle for some non-Galois extensions of number fields. Our main theorem is that for any square-free composite number $d$ which is divisible by at least one of $3$, $55$, $91$ or $95$, there exists a finite extension of degree $d$ for which the Hasse norm principle fails. To accomplish it, we determine the structure of the Tate--Shafarevich groups of norm one tori for finite extensions of degree $d$ under the normality of $p$-Sylow subgroups of the Galois groups of their Galois closures for a square-free prime factor $p$ of $d$. Moreover, we reduce the assertion to an investigation of $2$-dimensional $\mathbb{F}_p$-representations of some groups of order coprime to $p$., Comment: 39pages, comments are welcome

Published
2023

3. Note on Tamagawa numbers of tori attached to CM algebras

Author

Oki, Yasuhiro

Subjects
Mathematics - Number Theory
Abstract

We prove that any integer power of $2$ can be realized as the Tamagawa number of a torus attached to a CM algebra considered by Guo Sheu Yu and Liang Yang Yu. Such a result is obtained by Liang Yang Yu under assuming "a generalized Landau conjecture". The main contribution of this paper is to remove the above assumption., Comment: This article was superseded by arXiv:2109.04121

Published
2022

4. On Tamagawa numbers of CM tori

Author

Liang, Pei-Xin, Oki, Yasuhiro, Yang, Hsin-Yi, and Yu, Chia-Fu

Subjects
Mathematics - Number Theory
Abstract

In this article we investigate the problem of computing Tamagawa numbers of CM tori. This problem arises naturally from the problem of counting polarized abelian varieties with commutative endomorphism algebras over finite fields, and polarized CM abelian varieties and components of unitary Shimura varieties in the works of Achter--Altug--Garcia--Gordon and of Guo--Sheu--Yu, respectively. We make a systematic study on Galois cohomology groups in a more general setting and compute the Tamagawa numbers of CM tori associated to various Galois CM fields. Furthermore, we show that every (positive or negative) power of $2$ is the Tamagawa number of a CM tori, proving the analogous conjecture of Ono for CM tori., Comment: Four authors. Add Section 8 which is merged from results of arXiv:2206.15230 and Section 9, 38 pages

Published
2021
Full Text
View/download PDF

5. On the connected components of Shimura varieties for CM unitary groups in odd variables

Author

Oki, Yasuhiro

Subjects
Mathematics - Number Theory, Mathematics - Algebraic Geometry, 14G35, 20G30, 20G25
Abstract

We study the prime-to-$p$ Hecke action on the projective limit of the sets of connected components of Shimura varieties with fixed parahoric or Bruhat--Tits level at $p$. In particular, we construct infinitely many Shimura varieties for CM unitary groups in odd variables for which the considering actions are not transitive. We prove this result by giving negative examples on the question of Bruhat--Colliot-Th\'el\`ene--Sansuc--Tits or its variant, which is related to the weak approximation on tori over $\mathbb{Q}$., Comment: 20 pages, comments are welcome

Published
2021

6. Rapoport--Zink spaces for spinor groups with special maximal parahoric level structure

Author

Oki, Yasuhiro

Subjects
Mathematics - Number Theory, Mathematics - Algebraic Geometry
Abstract

In this article, we give a concrete description of the underlying reduced subscheme of the Rapoport--Zink spaces for spinor similitude groups with special maximal parahoric (and non-hyperspecial) level structure. Moreover, we give two applications of the above result. One of which is describing the structure of the basic loci of mod $p$ reductions of Kisin--Pappas integral models of Shimura varieties for spinor similitude groups with special maximal parahoric level structure at $p$. The other is constructing a variant of the result of He, Li and Zhu, which gives a formula on the intersection multiplicity of the GGP cycles associated codimension $1$ embeddings of Rapoport--Zink spaces for spinor similitude groups., Comment: 32 pages, continued from "Notes on Rapoport--Zink spaces of Hodge type with parahoric level structure". Comments are welcome

Published
2020

7. Notes on Rapoport--Zink spaces of Hodge type with parahoric level structure

Author

Oki, Yasuhiro

Subjects
Mathematics - Number Theory, Mathematics - Algebraic Geometry
Abstract

In this article, we treat two questions on Rapoport--Zink spaces of Hodge type constructed by Hamacher and Kim. One of which is their singularities, and the other is $p$-adic uniformization of Shimura varieties. More precisely, we prove that the singularity of a Rapoport--Zink space is controlled by its asssociated local model, and the basic locus of a Kisin--Pappas integral model of a Shimura variety is uniformized by the corresponding Rapoport--Zink space. These results extend the known facts by Rapoport and Zink in the case of PEL type., Comment: 18 pages, comments are welcome

Published
2020

8. On the supersingular locus of the Shimura variety for $\mathrm{GU}(2,2)$ over a ramified prime

Author

Oki, Yasuhiro

Subjects
Mathematics - Number Theory, Mathematics - Algebraic Geometry
Abstract

We study the structure of the supersingular locus of the Rapoport--Zink integral model of the Shimura variety for $\mathrm{GU}(2,2)$ over a ramified odd prime with the special maximal parahoric level. We prove that the supersingular locus equals the disjoint union of two basic loci, one of which is contained in the flat locus, and the other is not. We also describe explicitly the structures of basic loci. More precisely, the former one is purely $2$-dimensional, and each irreducible component is birational to the Fermat surface. On the other hand, the latter one is purely $1$-dimensional, and each irreducible component is birational to the projective line., Comment: 47 pages, comments are welcome

Published
2020

9. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, Park, Haeseong, Call, S Greg, Madwani, Kiran, Oki, Yasuhiro, Subbiah, Vivek, Hong, David S, Naing, Aung, Velez-Bravo, Vivianne M, Barnes, Tamara G, Hagemeister, Fredrick B, Falchook, Gerald S, Karp, Daniel D, Wheler, Jennifer J, Piha-Paul, Sarina A, Garrido-Laguna, Ignacio, Shpall, Elizabeth J, Fayad, Luis E, Neelapu, Sattva S, Meric-Bernstam, Funda, Kurzrock, Razelle, and Fanale, Michelle A

Subjects
Clinical Research, Clinical Trials and Supportive Activities, Lymphoma, Rare Diseases, Transplantation, Hematology, Cancer, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Brentuximab Vedotin, Dose-Response Relationship, Drug, Drug-Related Side Effects and Adverse Reactions, Everolimus, Female, Hematopoietic Stem Cell Transplantation, Histone Deacetylase Inhibitors, Histone Deacetylases, Hodgkin Disease, Humans, Male, Middle Aged, Recurrence, Sirolimus, Stem Cell Transplantation, TOR Serine-Threonine Kinases, Vorinostat, Young Adult, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposePreclinical and early clinical data suggested that combining histone deacetylase (HDAC) and mTOR inhibitors can synergistically inhibit Hodgkin lymphoma.Patients and methodsDuring the dose-escalation study (ClinicalTrials.gov number: NCT01087554) with the HDAC inhibitor vorinostat and the mTOR inhibitor sirolimus (V+S), a patient with Hodgkin lymphoma refractory to nine prior therapies demonstrated a partial response (PR) lasting for 18.5 months, which promoted additional enrollment of patients with Hodgkin lymphoma as well as exploration of an alternative combination of vorinostat and mTOR inhibitor everolimus (V+E).ResultsA total of 40 patients with refractory Hodgkin lymphoma received V+S (n = 22) or V+E (n = 18). Patients received a median of five prior therapies, including brentuximab (n = 39), autologous stem cell transplantation (n = 26), and allogeneic stem cell transplantation (n = 12). The most frequent grade ≥3 treatment-related adverse event was thrombocytopenia in 55% and 67% of patients treated with V+S and V+E, respectively. Complete response was reported in 6 (27%) patients treated with V+S and 2 (11%) patients treated with V+E, and PR was reported in 6 patients (27%) treated with V+S and 4 (22%) patients treated with V+E (objective response rate of 55% and 33%, respectively). In summary, combined HDAC and mTOR inhibition had encouraging activity in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma and warrants further investigation.ConclusionsCombined HDAC and mTOR inhibition has salutary activity in patients with relapsed refractory Hodgkin lymphoma and warrants further investigation.

Published
2020

10. On supersingular loci of Shimura varieties for quaternionic unitary groups of degree $2$

Author

Oki, Yasuhiro

Subjects
Mathematics - Number Theory, Mathematics - Algebraic Geometry, 11, 14
Abstract

We describe the structure of the supersingular locus of a Shimura variety for a quaternionic unitary similitude group of degree $2$ over a ramified odd prime $p$ if the level at $p$ is given by a special maximal compact open subgroup. More precisely, we show that such a locus has purely $2$-dimensional, and every irreducible component is birational to the Fermat surface. Furthermore, we have an estimation of the numbers of connected and irreducible components. To prove these assertions, we completely determine the structure of the underlying reduced scheme of the Rapoport--Zink space for the quaternionic unitary similitude group of degree $2$, with a special parahoric level. We prove that such a scheme is purely $2$-dimensional, and every irreducible component is isomorphic to the Fermat surface. We also determine its connected components, irreducible components and their intersection behaviors by means of the Bruhat--Tits building of $\mathrm{PGSp}_4(\mathbb{Q}_p)$. In addition, we compute the intersection multiplicity of the GGP cycles associated to an embedding of the considering Rapoport--Zink space into the Rapoport--Zink space for the unramified $\mathrm{GU}_{2,2}$ with hyperspecial level for the minuscule case., Comment: 66 pages

Published
2019
Full Text
View/download PDF

11. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL

Author

Cherng, Hua-Jay J., Alig, Stefan K., Oki, Yasuhiro, Nastoupil, Loretta J., Fayad, Luis, Neelapu, Sattva S., Turturro, Francesco, Hagemeister, Fredrick, Craig, Alexander F. M., Macaulay, Charles W., Rodriguez, Maria Alma, Lee, Hun Ju, McDonnell, Timothy J., Flowers, Christopher R., Vega, Francisco, Green, Michael R., Feng, Lei, Kurtz, David M., Alizadeh, Ash A., Davis, R. Eric, and Westin, Jason R.

Published
2023
Full Text
View/download PDF

14. Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes.

Author

Brammer, Jonathan, Chihara, Dai, Poon, L, Caimi, Paolo, de Lima, Marcos, Ledesma, Celina, Rondon, Gabriela, Ciurea, Stefan, Nieto, Yago, Fanale, Michelle, Dabaja, Bouthaina, Maziarz, Richard, Champlin, Richard, Hosing, Chitra, and Oki, Yasuhiro

Subjects
Extranodal natural killer/T-cell lymphoma, SMILE, advanced stage, refractory disease, stem cell transplant, Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Cohort Studies, Female, Humans, Lymphoma, Male, Middle Aged, Natural Killer T-Cells, Neoplasm Recurrence, Local, Prognosis, Stem Cell Transplantation, Young Adult
Abstract

BACKGROUND: Extra-Nodal natural killer/T-cell lymphoma (ENKL) is a rare lymphoma representing approximately 5-10% of T-cell non-Hodgkin lymphomas diagnosed in the United States each year. Patients with advanced stage III/IV ENKL and relapsed refractory ENKL have a poor prognosis even despite aggressive therapy and stem cell transplantation (SCT). We conducted a review of the management of 37 patients with advanced-stage and relapsed/refractory ENKL in a predominantly non-Asian cohort evaluating both chemotherapy and SCT outcomes. PATIENTS AND METHODS: We evaluated clinical outcomes in all patients treated for advanced stage III/IV or relapsed/refractory ENKL at MD Anderson cancer center between 2000-2014. Next, we collected stem cell transplant data from four transplant institutions to further evaluate outcomes of both allogeneic (allo-SCT) and autologous (auto-SCT) stem cell transplantation in ENKL. RESULTS: OS and PFS were 73% and 45% at one year, and 30% and 19% at 3-years, respectively. SMILE chemotherapy was more effective in maintaining a CR compared to CHOP (83% vs 17%). Only achievement of CR was prognostic for OS (HR 0.245, p=0.002) and PFS (HR 0.072, p) CONCLUSION: Our results suggest that achievement of a CR is imperative in patients with advanced ENKL, and is desirable for any patient for whom auto-SCT is utilized. SMILE-based chemotherapy appeared effective in attaining a CR, and was also an effective salvage regimen. For patients attaining a first CR, auto-SCT should be strongly considered, but should definitely be utilized in patients attaining CR2. For patients with refractory disease, allo-SCT can be considered in a selected group of patients.

Published
2018

16. Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study

Author

Kim, Won Seog, Oki, Yasuhiro, Kim, Seok Jin, Yoon, Sang Eun, Ardeshna, Kirit M., Lin, Yi, Ruan, Jia, Porcu, Pierluigi, Brammer, Jonathan E., Jacobsen, Eric D., Yoon, Dok Hyun, Suh, Cheolwon, Suarez, Felipe, Radford, John, Budde, Lihua E., Kim, Jin Seok, Bachy, Emmanuel, Lee, Hun Ju, Bollard, Catherine M., Jaccard, Arnaud, Kang, Hye Jin, Inman, Shannon, Murray, Maryann, Combs, Katherin E., Lee, Daniel Y., Advani, Ranjana, Gunter, Kurt C., Rooney, Cliona M., and Heslop, Helen E.

Published
2021
Full Text
View/download PDF

17. NK-Cell Lymphomas

Author

Chihara, Dai, Oki, Yasuhiro, Rosen, Steven T., Series Editor, Querfeld, Christiane, editor, and Zain, Jasmine, editor

Published
2019
Full Text
View/download PDF

19. Atypical lymphoproliferative disorder-clinical and pathological features

Author

Wilmas, Kelly, Duvic, Madeleine, and Oki, Yasuhiro

Abstract

Definitive diagnosis of cutaneous lymphoproliferative disorders is one of the most challenging issues in dermatopathology owing to the broad spectrum of clinical and histopathological presentations. We report a case of a 73-year-old woman who presented with a single, asymptomatic plaque limited to her left collarbone. This was followed by the appearance of several plaques and patches in addition to a tumor. Her initial biopsy suggested a CD4/CD8 double negative mycosis fungoides (MF). However, the rapidly progressive course of her disease is worrisome for peripheral T-cell lymphomas-not otherwise specified (PTCL-NOS). Subsequent biopsies revealed epidermal spongiosis with subepidermal edema and possible nodal involvement by cutaneous T-cell lymphoma. The rare combination of these pathologic features demonstrates the difficulty of diagnosing atypical lymphoproliferative disorders.

Published
2016

20. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

Author

Takahashi, Koichi, Sivina, Mariela, Hoellenriegel, Julia, Oki, Yasuhiro, Hagemeister, Fredrick B, Fayad, Luis, Romaguera, Jorge E, Fowler, Nathan, Fanale, Michelle A, Kwak, Larry W, Samaniego, Felipe, Neelapu, Sattva, Xiao, Lianchun, Huang, Xuelin, Kantarjian, Hagop, Keating, Michael J, Wierda, William, Fu, Kai, Chan, Wing C, Vose, Julie M, O'Brien, Susan, Davis, Richard E, and Burger, Jan A

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cancer, Rare Diseases, Lymphoma, Hematology, Clinical Research, Aetiology, 2.1 Biological and endogenous factors, Adenine, Antineoplastic Agents, B-Cell Activation Factor Receptor, Biomarkers, Tumor, Cell Line, Tumor, Chemokine CCL3, Chemokine CCL4, Enzyme-Linked Immunosorbent Assay, Epidemiologic Methods, Humans, Lymphoma, Large B-Cell, Diffuse, Piperidines, Prognosis, Pyrazoles, Pyrimidines, Signal Transduction, chemokines, diffuse large B-cell lymphoma, lymphoma, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

B cell receptor (BCR) signalling is an important pathway in diffuse large B cell lymphoma (DLBCL). In response to BCR triggering, normal and malignant B cells secrete the chemokines CCL3 and CCL4 to attract accessory cells to the tissue microenvironment. We measured CCL3 and CCL4 serum concentrations in 102 patients with newly diagnosed DLBCL by enzyme-linked immunosorbent assay, investigated their prognostic impact and validated our findings in an independent cohort of 51 patient samples. We also tested CCL3 and CCL4 secretion by DLBCL cells, and the influence of BTK inhibitors on the secretion of these chemokines. High CCL3 (≥40 pg/ml) serum concentrations correlated with higher international prognostic index, lactate dehydrogenase and β2 microglobulin, as did CCL4 (≥180 pg/ml) with advanced Ann Arbor stages. High CCL3 levels correlated with significantly shorter progression-free and overall survival. The in vitro studies demonstrated that activated B cell-like, but not germinal centre B cell-like DLBCL cells, secrete high levels of CCL3 and CCL4 after BCR triggering, which was exquisitely sensitive to BCR pathway inhibition. These findings support CCL3 and CCL4 protein concentrations as biomarkers for BCR pathway activation and prognosis in DLBCL.

Published
2015

25. POSTER: TCL-275 Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients With Relapsed or Refractory T-Cell Lymphoma (TCL) With Survival Analysis

Author

Iyer, Swaminathan, primary, Prakash, Rishab, additional, Feng, Lei, additional, Agbedia, Owhofasa, additional, Xu, Jie, additional, Lee, Hun Ju, additional, Malpica, Luis, additional, Ahmed, Sairah, additional, Oki, Yasuhiro, additional, Chihara, Dai, additional, Peyton, Karen, additional, Steiner, Raphael, additional, Nastoupil, Loretta, additional, Fayad, Luis, additional, Vega, Francisco, additional, Flowers, Christopher, additional, Neelapu, Sattva, additional, and Nair, Ranjit, additional

Published
2023
Full Text
View/download PDF

26. TCL-275 Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients With Relapsed or Refractory T-Cell Lymphoma (TCL) With Survival Analysis

Author

Iyer, Swaminathan, primary, Prakash, Rishab, additional, Feng, Lei, additional, Agbedia, Owhofasa, additional, Xu, Jie, additional, Lee, Hun Ju, additional, Malpica, Luis, additional, Ahmed, Sairah, additional, Oki, Yasuhiro, additional, Chihara, Dai, additional, Peyton, Karen, additional, Steiner, Raphael, additional, Nastoupil, Loretta, additional, Fayad, Luis, additional, Vega, Francisco, additional, Flowers, Christopher, additional, Neelapu, Sattva, additional, and Nair, Ranjit, additional

Published
2023
Full Text
View/download PDF

28. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma

Author

Nieto, Yago, Thall, Peter F., Ma, Junsheng, Valdez, Benigno C., Ahmed, Sairah, Anderlini, Paolo, Popat, Uday, Jones, Roy B., Shpall, Elizabeth J., Hosing, Chitra, Qazilbash, Muzaffar, Kebriaei, Partow, Alousi, Amin, Timmons, Melissa, Gulbis, Alison, Myers, Alan, Oki, Yasuhiro, Fanale, Michelle, Dabaja, Bouthaina, Pinnix, Chelsea, Milgrom, Sarah, Champlin, Richard, and Andersson, Borje S.

Published
2018
Full Text
View/download PDF

29. Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy

Author

Pinnix, Chelsea C., Cella, Laura, Andraos, Therese Y., Ayoub, Zeina, Milgrom, Sarah A., Gunther, Jillian, Thosani, Sonali, Wogan, Christine, Conson, Manuel, D'Avino, Vittoria, Oki, Yasuhiro, Fanale, Michelle, Lee, Hun J., Neelapu, Sattva, Fayad, Luis, Hagemeister, Frederick, Rodriguez, M. Alma, Nastoupil, Loretta J., Nieto, Yago, Qiao, Wei, Pacelli, Roberto, and Dabaja, Bouthaina

Published
2018
Full Text
View/download PDF

31. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma

Author

Milgrom, Sarah A., Pinnix, Chelsea C., Chi, T. Linda, Vu, Thinh H., Gunther, Jillian R., Sheu, Tommy, Fowler, Nathan, Westin, Jason R., Nastoupil, Loretta J., Oki, Yasuhiro, Fayad, Luis E., Neelapu, Sattva, Rodriguez, Maria Alma, Hagemeister, Frederick B., Fanale, Michelle A., Lee, Hun J., Hosing, Chitra, Ahmed, Sairah, Nieto, Yago, Shpall, Elizabeth J., and Dabaja, Bouthaina S.

Published
2018
Full Text
View/download PDF

33. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Author

Horwitz, Steven M., Koch, Raphael, Porcu, Pierluigi, Oki, Yasuhiro, Moskowitz, Alison, Perez, Megan, Myskowski, Patricia, Officer, Adam, Jaffe, Jacob D., Morrow, Sara N., Allen, Kerstin, Douglas, Mark, Stern, Howard, Sweeney, Jennifer, Kelly, Patrick, Kelly, Virginia, Aster, Jon C., Weaver, David, Foss, Francine M., and Weinstock, David M.

Published
2018
Full Text
View/download PDF

34. Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation

Author

Akhtari, Mani, Milgrom, Sarah A., Pinnix, Chelsea C., Reddy, Jay P., Dong, Wenli, Smith, Grace L., Mawlawi, Osama, Abou Yehia, Zeinab, Gunther, Jillian, Osborne, Eleanor M., Andraos, Therese Y., Wogan, Christine F., Rohren, Eric, Garg, Naveen, Chuang, Hubert, Khoury, Joseph D., Oki, Yasuhiro, Fanale, Michelle, and Dabaja, Bouthaina S.

Published
2018
Full Text
View/download PDF

37. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte–predominant Hodgkin lymphoma

Author

Fanale, Michelle A., Cheah, Chan Yoon, Rich, Amy, Medeiros, L.Jeffrey, Lai, Chao-Ming, Oki, Yasuhiro, Romaguera, Jorge E., Fayad, Luis E., Hagemeister, F.B., Samaniego, Felipe, Rodriguez, Maria A., Neelapu, Sattva S., Lee, Hun J., Nastoupil, Loretta, Fowler, Nathan H., Turturro, Francesco, Westin, Jason R., Wang, Michael L., McLaughlin, Peter, Pinnix, Chelsea C., Milgrom, Sarah A., Dabaja, Bouthaina, Horowitz, Sandra B., and Younes, Anas

Published
2017
Full Text
View/download PDF

41. A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma

Author

Milgrom, Sarah A., Elhalawani, Hesham, Lee, Joonsang, Wang, Qianghu, Mohamed, Abdallah S. R., Dabaja, Bouthaina S., Pinnix, Chelsea C., Gunther, Jillian R., Court, Laurence, Rao, Arvind, Fuller, Clifton D., Akhtari, Mani, Aristophanous, Michalis, Mawlawi, Osama, Chuang, Hubert H., Sulman, Erik P., Lee, Hun J., Hagemeister, Frederick B., Oki, Yasuhiro, Fanale, Michelle, and Smith, Grace L.

Published
2019
Full Text
View/download PDF

45. Supplementary File 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figure 6 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

47. Supplementary File 1 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure 5 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Table 1, Supplementary Table 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results